CARMELINA®

Evaluating the CV and kidney safety profile of linagliptin versus placebo in patients with T2D at high vascular risk

CARMELINA®
Rate this content
  • CARMELINA®
  • Contents
  • Contents
  • DPP-4 inhibitors are a common treatment option for glucose lowering in patients with T2D
  • DPP-4 inhibitors have demonstrated safety for 3P-MACE
Add to a new presentation
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go
Add to an existing presentation
Cancel